Transliteration & Translation for ACTD: Notarization, Apostille, and QA Proofing Without Delays ACTD Language Operations: How to Translate, Transliterate, Legalize, and Prove Quality Translation vs. Transliteration in ACTD: What They Mean, Where They Live, and Why Timelines Depend on Them In ASEAN Common Technical Dossier (ACTD) filings, translation converts content into a new language (e.g., English → Thai, English → Bahasa Indonesia), while transliteration converts the spelling of names written in one script to another (e.g., company name in Latin characters rendered in Thai script). Both activities primarily surface in Module 1 (administrative forms, declarations, labeling leaflets, carton/container artwork) but…

Bridging Data from a CTD Core to ACTD: What Truly Needs CMC and Clinical Re-work From CTD to ACTD: Pinpointing the CMC and Clinical Re-work Your Dossier Really Needs Bridge, Don’t Rewrite: The Philosophy, Scope, and Boundaries of CTD→ACTD Conversion When a US/EU dossier travels to ACTD markets, teams often ask, “What must we rewrite?” In most cases the correct answer is: very little science—lots of framing. A bridge is a concise, reviewer-facing explanation that preserves the CTD-true evidence while adapting navigation, headings, and country wrappers so assessors can verify claims quickly. Good bridges change how proof is presented, not…

Bioequivalence & Biowaivers in ACTD: Study Designs and Acceptance Patterns (US-First Guide) ACTD Bioequivalence & Biowaivers: Designs, Dissolution, and Acceptance Patterns That Travel Globally Regulatory Baseline: What “Bioequivalence” Means in ACTD and How It Aligns with CTD/EU/US Bioequivalence (BE) shows that the test and reference products exert comparable exposure at the site of action, typically assessed via rate and extent of absorption using PK endpoints (AUC and Cmax) under standardized conditions. In the ACTD wrapper, the scientific core mirrors ICH/CTD principles: two one-sided tests (TOST) on log-transformed metrics, demonstrating that the 90% confidence interval of the geometric mean ratio (test/reference)…

Device–Drug Combinations in ACTD: Placement, Testing Evidence, and Local Annexes ACTD Strategy for Device–Drug Combos: Where to Place Content, What to Prove, and How to Localize What Counts as a Device–Drug Combination—and Why ACTD Placement Matters More Than You Think A device–drug combination is any product in which a medical device and a medicinal product are physically or functionally integrated to achieve the intended clinical effect—think prefilled syringes (PFS), autoinjectors/pen injectors, on-body delivery systems, drug-eluting stents, medicated plasters/patches, inhalers with dose counters, and ophthalmic droppers with valve systems. Scientifically, your CTD core already contains the right building blocks—drug substance/product quality…

API/Excipient Source Changes in ACTD: Filing Expectations, Evidence Design, and Supplier Qualification Changing API or Excipient Sources for ACTD Markets: What to File, How to Prove Equivalence, and Ship Without Delays Why API/Excipient Source Changes Draw Scrutiny: Risk Logic, Lifecycle Impact, and the ACTD Wrapper Switching an API supplier or excipient source is one of the most sensitive lifecycle moves you can make, because it potentially touches identity, purity, performance, and patient risk. In the United States, these changes are routed through defined supplement types (e.g., PAS/CBE-30/CBE-0 for NDAs/ANDAs) with clear expectations for evidence and timelines. ACTD authorities apply the…

Timelines and Queues in Key ACTD Countries: How to Plan from a US Launch Planning ACTD Submissions from a US CTD: Country Queues, Portal Behaviors, and Scheduling That Works Why ACTD Timelines Feel Different: Queue Physics, Administrative Friction, and the US→ASEAN Shift Moving a US-built CTD into ACTD markets is not just a file conversion—it is a shift in queue dynamics. In the United States, many dossier steps are stabilized by eCTD infrastructure and well-trodden supplement pathways. In ASEAN jurisdictions that adopt the ASEAN Common Technical Dossier (ACTD) wrapper, reviewers still evaluate the same science, but administrative and localization steps—Module…

ACTD Country Annexes: Build Once, Localize Many Without Rewriting the Science Reusable ACTD Country Annexes: Localize Fast, Keep the Evidence Intact What a Country Annex Really Is: Scope, Boundaries, and the Reuse Mindset In ACTD markets, a country annex is the small set of local artifacts that wrap your unchanged CTD evidence so reviewers can accept, read, and verify it inside their national process. Think of it as an adapter: Module 1 forms and declarations, legalized corporate documents, localized labeling and artwork, agent/MAH particulars, and any administrative statements that anchor the same CMC, nonclinical, and clinical proof you used elsewhere….

Common ACTD Deficiencies Cited by Regulators—and How to Prevent Them ACTD Review Findings You Can Predict—and Eliminate—Before You File The Anatomy of ACTD Findings: Why Good Science Still Draws Deficiencies Most ASEAN Common Technical Dossier (ACTD) deficiencies do not question your science; they expose discoverability and identity breaks that make it hard for reviewers to verify the science quickly. Agencies typically cite three clusters of problems. First, Module 1 and identity mismatches: product names, strengths, MAH/site addresses, or signatory titles that differ across forms, legalized documents, and artwork. Second, evidence traceability gaps: Module 2 statements that do not “click through”…

Harmonizing ACTD with CTD for Multinational Launches: Governance and RACI That Scales Make One Global Dossier Work Everywhere: Governance & RACI for CTD→ACTD Rollouts Why Harmonization Matters: One Science Core, Many National Wrappers Launching across the United States, Europe, and ACTD markets is less about authoring more content and more about controlling sameness. The science—your CTD core across Modules 2–5—should remain frozen and traceable; the wrapper—Module 1 forms, translations, legalizations, and portal packaging—must flex per country. Teams that do not distinguish these tiers end up with multiple “truths” for the same claim, creating version drift, query loops, and rework during…

QA for ACTD Dossiers: File Integrity, Cross-References, and Leaf-Title Checks Quality-Assuring ACTD Dossiers: Integrity, Navigation, and Naming That Accelerate Review The QA Mission for ACTD: From “Looks Fine” to “Provably Correct” Files In ASEAN Common Technical Dossier (ACTD) markets, many first-cycle delays come from problems that have nothing to do with your science. They arise because reviewers cannot open, search, or navigate your files quickly—or because the same concept is named three different ways across forms, labels, and filenames. A disciplined quality assurance (QA) program converts those soft spots into predictable wins. Its job is to transform “the PDF looks…